Jim Wassil Sells 3,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) Stock

Vaxcyte, Inc. (NASDAQ:PCVXGet Free Report) COO Jim Wassil sold 3,000 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $71.99, for a total value of $215,970.00. Following the transaction, the chief operating officer now owns 213,503 shares of the company’s stock, valued at $15,370,080.97. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Vaxcyte Trading Down 1.3 %

PCVX opened at $72.51 on Friday. The firm has a market cap of $7.89 billion, a price-to-earnings ratio of -16.94 and a beta of 0.97. The stock’s 50-day moving average price is $66.35 and its 200 day moving average price is $65.51. Vaxcyte, Inc. has a 12-month low of $44.20 and a 12-month high of $82.04.

Vaxcyte (NASDAQ:PCVXGet Free Report) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.28. On average, research analysts forecast that Vaxcyte, Inc. will post -3.96 earnings per share for the current year.

Institutional Investors Weigh In On Vaxcyte

A number of hedge funds have recently bought and sold shares of PCVX. Darwin Global Management Ltd. raised its position in Vaxcyte by 374.3% in the 1st quarter. Darwin Global Management Ltd. now owns 2,750,804 shares of the company’s stock valued at $187,907,000 after purchasing an additional 2,170,845 shares in the last quarter. Vanguard Group Inc. raised its position in Vaxcyte by 15.2% in the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after purchasing an additional 1,284,883 shares in the last quarter. Westfield Capital Management Co. LP acquired a new stake in Vaxcyte in the 3rd quarter valued at about $51,180,000. Norges Bank acquired a new stake in Vaxcyte in the 4th quarter valued at about $57,494,000. Finally, Capital Research Global Investors raised its position in Vaxcyte by 20.4% in the 1st quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after purchasing an additional 700,414 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on PCVX shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Vaxcyte in a research note on Thursday, May 9th. Needham & Company LLC reissued a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research note on Thursday, May 9th.

Check Out Our Latest Stock Analysis on Vaxcyte

About Vaxcyte

(Get Free Report)

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

See Also

Insider Buying and Selling by Quarter for Vaxcyte (NASDAQ:PCVX)

Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.